Fulgent Genetics (FLGT) Soars 6.6%: Is Further Upside Left in the Stock?Zacks Investment Research • 07/18/24
Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024Business Wire • 07/11/24
Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global MarketingGlobeNewsWire • 06/10/24
Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck CancerBusiness Wire • 06/03/24
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual MeetingBusiness Wire • 05/24/24
Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer TherapeuticsBusiness Wire • 05/14/24
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/03/24
Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024Business Wire • 04/11/24
Fulgent Genetics to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024Business Wire • 02/13/24
Cord Blood Registry® (CBR®) by CooperSurgical® and Fulgent Genetics Launch Innovative Genetic TestingPRNewsWire • 02/09/24
Fulgent to Participate in the Piper Sandler 35th Annual Healthcare ConferenceBusiness Wire • 11/14/23
Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual MeetingBusiness Wire • 11/03/23
Fulgent Genetics, Inc. (FLGT) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/03/23
Fulgent Genetics to Announce Third Quarter 2023 Financial Results on Friday November 3, 2023Business Wire • 10/17/23